Table 1.
List of adverse reactions in patients with mismatch repair-deficient endometrial cancer receiving Dostarlimab in the GARNET study.
| Adverse reaction | Dostarlimab (N = 104)a |
|
|---|---|---|
| All grades (%) | Grade 3 or 4 (%) | |
| General and administration site | ||
| Fatigueb | 48 | 1 |
| Gastrointestinal disorders | ||
| Nausea | 30 | 0 |
| Diarrhea | 26 | 1.9 |
| Constipation | 20 | 0.9 |
| Vomiting | 18 | 0 |
| Blood and lymphatic system | ||
| Anemiac | 24 | 13 |
| Metabolism and nutrition | ||
| Decreased appetite | 14 | 0 |
| Respiratory, thoracic, and mediastinal | ||
| Cough | 14 | 0 |
| Skin and subcutaneous tissue | ||
| Pruritus | 14 | 1 |
| Infections | ||
| Urinary tract infection | 13 | 1.9 |
| Musculoskeletal and connective tissue | ||
| Myalgia | 12 | 0 |
Toxicity was graded per the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03.
a
Intent-to-treat (ITT) population (N = 104).
b
Includes fatigue and asthenia.
c
Includes anemia, hemoglobin decrease, iron deficiency, and iron deficiency.26